Life Expectancy Predicted by Decision-Analytic Models for Cancer Screening

A new study on oncology-colorectal cancer has revealed that current decision-analytic models evaluating the effects of cancer screening may not accurately reflect the true benefits of screening. The research, published in Medical Decision Making, found that models predicting life expectancy gains from screening interventions varied in magnitude across different cancer types. The study highlights the importance of considering competing mortality risks in decision-analytic models to improve the accuracy of benefit-harm assessments in cancer screening.

Key Takeaways:

• The study aimed to systematically assess methodological competing mortality risk features that affect the translation of cancer-specific mortality reductions into gains in life expectancy in decision-analytic screening models for prostate, lung, breast, and colorectal cancer.
• Literature databases were systematically searched for clinical and economic decision-analytic models evaluating the effect of screening for the mentioned cancer types compared with no screening.
• Forty-two clinical and economic decision-analytic models were included for narrative synthesis, and basic information and specific methodological features of the included decision-analytic models were extracted using a standardized approach.
• All included models predicted gains in life expectancy with screening, although the magnitude of these gains varied both within and across cancer types.
• Models that considered competing mortality risks tended to predict smaller lifetime gains from screening interventions.
• The research concluded that future studies should prioritize the use of advanced modeling approaches that account for competing mortality risks to improve the accuracy of benefit-harm assessments in cancer screening.
• The study was conducted by researchers from the Institute for Public Health at the University of Innsbruck, with Uwe Siebert as the lead author.
• The research has important implications for public health policy and decision-making, highlighting the need for more accurate and nuanced models of cancer screening benefits and risks.

Statistics:

• 42 decision-analytic models were included in the review
• The magnitude of predicted life expectancy gains from screening interventions varied across different cancer types
• Gains in life expectancy were predicted by all included models, but the magnitude of these gains varied both within and across cancer types
• Models considering competing mortality risks tended to predict smaller lifetime gains from screening interventions

Sources:

• Life Expectancy Predicted By Decision-analytic Models Evaluating Screening for Prostate, Lung, Breast, and Colorectal Cancer: a Systematic Review Focusing On Competing Mortality Risks. Medical Decision Making, 2025.
• Hall in Tirol, Austria, University of Innsbruck, Institute for Public Health.
• Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA.